INDICATIONS
Simeprevir is indicated for use in combination with peginterferon alfa and ribavirin in the treatment of chronic hepatitis C virus (HCV) genotype 1 in adult patients with compensated liver disease, including cirrhosis. Screening patients with HCV genotype 1a for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended; alternative therapy should be considered for patients who have the virus with this polymorphism, because simeprevir effi cacy in combination with peginterferon alfa and ribavirin is substantially reduced in this population.
1 Table 1 compares the US Food and Drug Administration (FDA)-approved indications for HCV antiviral agents. [1] [2] [3] [4] 
CLINICAL PHARMACOLOGY
Simeprevir is an HCV NS3/4A protease inhibitor. Simeprevir produces a rapid reduction in plasma HCV RNA levels. Within days, there is a steep reduction of HCV RNA, followed by a more gradual decline. The median maximal reduction was 3.9 log 10 units/mL and occurred at a median of 6 days. 5 Simeprevir has activity as a monotherapy against HCV genotypes 1, 2, 4, 5, and 6. It is not effective against HCV genotype 3. [6] [7] [8] Reduced susceptibility has been observed in HCV carrying amino acid substitutions at NS3 positions F43, Q80, R155, A156, and/or D168; substitutions at D168V or A and R155K displayed the greatest Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2014 monograph topics are dapaglifl ozin, tasimelteon, treprostinil diolamine, avarofl oxacin, and idelalisib. The DUE/MUE is on dapaglifl ozin. 1 Simeprevir is extensively plasma protein bound (greater than 99.9%), primarily to albumin. 1 The terminal elimination half-life of simeprevir is 10 to 13 hours in HCV-uninfected subjects and 41 hours in HCV-infected subjects receiving a 200 mg dose. 1 Simeprevir is metabolized in the liver, primarily via oxidative metabolism by the hepatic cytochrome P450 3A (CYP3A) system. Elimination is via biliary excretion; renal clearance is insignifi cant. Unchanged simeprevir in feces accounts for 31% of the administered dose. 1 Simeprevir exposure was increased 2.4-fold in HCV-uninfected subjects with moderate hepatic impairment (Child Pugh class B) and 5.2-fold in HCV-uninfected subjects with severe hepatic impairment (Child Pugh class C). Simeprevir pharmacokinetics have not been assessed in HCVinfected patients with moderate to severe hepatic impairment. Liver fi brosis stage did not have a clinically important effect on simeprevir pharmacokinetics. 1 Simeprevir exposure is increased in Asian patients compared with White patients, with a mean simeprevir plasma exposure 3.4-fold higher. 1 Age, renal function, weight, and gender appear to have no clinically important effect on simeprevir pharmacokinetics. 1, 8 Comments: These guidelines were published prior to the availability of simeprevir; however, the NS3/4A protease inhibitors (boceprevir and telaprevir) are included in the guideline. The optimal therapy recommended by the guideline for chronic HCV genotype 1 infection is the use of boceprevir or telaprevir in combination with peginterferon alfa and ribavirin. The NS3/4A protease inhibitors should not be used without peginterferon alfa and weight-based ribavirin. 
Secondary Endpoint(s)
• A rapid viral response (HCV undetectable at 4 weeks) was achieved in 68% to 76% of the patients treated with a simeprevir-containing regimen, of whom 88% to 95% subsequently achieved SVR24; 5.2% of patients in the placebo arm experienced a rapid viral response.
• SVR12 was achieved in 76% to 86% of the patients treated with a simeprevir-containing regimen compared with 66% treated with control.
• SVR24 was achieved in 75% to 86% of the patients treated with a simeprevir-containing regimen compared with 65% treated with control (P < .05 vs control except for the regimen containing simeprevir 75 mg for 24 weeks).
• 79% to 86% of the simeprevir-treated patients were able to complete treatment at week 24.
• Among patients with undetectable HCV RNA at the end of treatment, viral relapse was less frequent in the simeprevir-treated patients (12% vs 18%).
• Fatigue scores over the 72-week study period were lower in the simeprevir-treatment groups (P < .001), likely due to the shorter mean treatment duration in these groups; rates of anemia, neutropenia, and rash did not differ between simeprevir and placebo.
Endpoint(s)
• Overall SVR24 rates were lower for patients with HCV genotype 1a (66%) compared with patients with HCV genotype 1b (89%), although SVR24 rates in genotype 1a and 1b patients treated with simeprevir 150 mg were similar (82% and 84%, respectively).
• A predictive value of the IL28B genotype and serum IP-10 response was found in the peginterferon and ribavirin treatment arm, but it had limited predictive value in patients treated with simeprevir, peginterferon, and ribavirin. 14 • PILLAR allowed 53 patients with a Metavir score of F3 (moderate periportal infl ammation, piecemeal necrosis or severe focal cell damage, some fi brosis, and no obvious cirrhosis) to be enrolled. The SVR24 in the treatment-naive F3 patients was 79% with simeprevir, peginterferon, and ribavirin versus 72% with peginterferon and ribavirin. 15 SVR72 rates were 82% and 85% with simeprevir 75 and 150 mg, respectively, and 64% with placebo in patients with Metavir scores of F0 to F2. For patients with F3 scores, SVR72 rates were 63% and 75% with simeprevir 75 and 150 mg, respectively, and 71% with placebo. 13 • Among patients with HCV genotype 1a, those without the Q80K polymorphism at baseline experienced a higher SVR24 rate (71% and 86%, respectively with simeprevir 75 and 150 mg) compared with those with the Q80K polymorphism (55% and 67%, respectively, with simeprevir 75 and 150 mg). Comments: The addition of simeprevir to the peginterferon and ribavirin regimen produced an increased sustained viral release without increasing the incidence of fatigue. 16 Subtle differences between simeprevir 75 and 150 mg doses in response rates in patients with the 1a genotype, non-CC IL28B genotypes, higher body mass index (BMI), and Metavir F3 scores prompted selection of the 150 mg dose for further study. The study was conducted in 13 countries in North America, Europe, and Asia-Pacifi c regions; 68% of patients were enrolled in Europe, 21% in North America, and 11% in Australia and New Zealand. A similar smaller study (DRAGON) conducted in Japan assessed simeprevir 50 or 100 mg once daily with peginterferon alfa-2a and ribavirin in patients with HCV genotype 1, achieving SVR24 rates of 77% to 92% with simeprevir-containing regimens compared with 46% with placebo plus peginterferon and ribavirin. Study Design: Randomized, phase 3, double-blind, multicenter study Study Funding: Janssen Research Patients: 394 treatment-naive patients with chronic HCV genotype-1 infection, compensated liver disease (including cirrhosis), and HCV RNA of at least 10,000 units/mL Intervention: Patients were randomized 2:1 to treatment with simeprevir 150 mg once daily plus peginterferon alfa-2a and ribavirin or placebo plus peginterferon alfa-2a and ribavirin for 12 weeks. Peginterferon alfa-2a 180 mcg was given as an injection once each week. Ribavirin was taken as a tablet twice daily at a dose determined by the patient's body weight. Peginterferon alfa-2a and ribavirin were continued in placebo-treated patients for an additional 36 weeks (48 weeks total). The total duration of peginterferon alfa2a and ribavirin therapy in the simeprevir-treated patients was based on response-guided criteria. If the HCV RNA was less than 25 units/mL at week 4 and undetectable at week 12, therapy was stopped at week 24. Therapy was continued to week 48 for those who did not achieve these criteria.
Results Primary Endpoint(s)
• SVR12 was 80% in the simeprevir-treated group and 50% in the placebo group (P < .001).
Secondary Endpoint(s)
• Rapid viral response was achieved by 80% of the simeprevir-treated group and 12% of the placebo-treated group.
• On-treatment failure rate was 9% in the simeprevir-treated group and 34% in the placebo-treated group.
• Relapse rate was 9% in the simeprevir-treated group and 21% in the placebo-treated group. Comments: Eighty-fi ve percent of the simeprevirtreated group met the response-guided therapy criteria and had their therapy discontinued at week 24. Presented data were from an analysis conducted at week 60. Limitations: Data are only available as a meeting abstract and in the prescribing information. Study Design: Randomized, phase 3, double-blind, multicenter study Study Funding: Janssen Research Patients: 391 treatment-naive patients with chronic HCV genotype-1 infection, compensated liver disease (including cirrhosis), and HCV RNA of at least 10,000 units/mL. Intervention: Patients were randomized 2:1 to treatment with simeprevir 150 mg once daily plus peginterferon alfa-2 and ribavirin or placebo plus peginterferon alfa-2 and ribavirin for 12 weeks. Peginterferon alfa-2a 180 mcg was given as an injection once each week and peginterferon alfa-2b was given as an injection once each week at a dose determined by the patient's body weight. Ribavirin was taken as a tablet twice daily at a dose determined by the patient's body weight. Peginterferon alfa-2 and ribavirin were continued in placebo-treated patients for additional 36 weeks (48 weeks total). The total duration of peginterferon alfa-2 and ribavirin therapy in the simeprevirtreated patients was based on response-guided criteria. If the HCV RNA was less than 25 units/mL at week 4 and undetectable at week 12, therapy was stopped at week 24. Therapy was continued to week 48 for those who did not achieve these criteria.
Results Primary Endpoint(s)
• SVR12 was 81% in the simeprevir-treated group and 50% in the placebo-treated group (P < .001).
Secondary Endpoint(s)
• Rapid viral response was achieved in 79% of the simeprevir-treated group and 13% of the placebo-treated group.
• On-treatment failure rate was 7% in the simeprevir-treated group and 32% in the placebo-treated group.
• Relapse rate was 13% in the simeprevir-treated group and 24% in the placebo-treated group. • SVR12 in patients treated with peginterferon alfa-2a was 88% in the simeprevir-treated group and 62% in the placebo-treated group. • SVR12 in patients treated with peginterferon alfa-2b was 78% in the simeprevir-treated group and 42% in the placebo-treated group.
• SVR12 for patients with a Metavir score of F0 to F2 was 85% in the simeprevir-treated group and 51% in the placebo-treated group.
• SVR12 for patients with a Metavir score of F3 to F4 was 66% in the simeprevir-treated group and 47% in the placebo-treated group. Comments: Study allowed the use of peginterferon alfa-2a and peginterferon alfa-2b. In the simeprevirtreated group, 86% met the response-guided therapy criteria and had their therapy discontinued at week 24. Presented data were from an analysis conducted at week 60. In pooled data from this study and the QUEST 1 study, SVR12 rates were lower in patients with the Q80K polymorphism at baseline than those without the Q80K polymorphism. Among patients with HCV genotype 1a, SVR12 was achieved in 84% of simeprevir-treated patients without the polymorphism compared with 43% of placebo-treated patients without the polymorphism, and in 58% of simeprevir-treated patients with the polymorphism compared with 52% of placebo-treated patients with the polymorphism.
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Limitations: Data are only available as a meeting abstract and in the prescribing information.
Drug:
, and HCV RNA of at least 10,000 units/mL (84% had HCV RNA greater than 800,000 units/mL; 15% had Metavir score F3 and 15% had Metavir score F4; 42% had HCV genotype 1a and 58% had HCV genotype 1b; 13% overall and 31% with genotype 1a virus had the NS3 Q80K polymorphism at baseline), who had relapsed after therapy with peginterferon and ribavirin; median age was 52 years; 66% of patients were male and 94% were White. Intervention: Simeprevir 150 mg once daily plus peginterferon alfa-2 and ribavirin or placebo plus peginterferon alfa-2 and ribavirin for 12 weeks. Peginterferon alfa-2a 180 mcg was given as an injection once each week. Ribavirin was taken as a tablet twice daily at a dose determined by the patient's body weight. Peginterferon alfa-2a and ribavirin were continued in placebo-treated patients for an additional 36 weeks (48 weeks total). The total duration of peginterferon alfa-2 and ribavirin therapy in the simeprevir-treated patients was based on response-guided criteria. If the HCV RNA was less than 25 units/mL at week 4 and undetectable at week 12, therapy was stopped at week 24. Therapy was continued to week 48 for those who did not achieve these criteria.
Results Primary Endpoint(s)
• SVR12 was 79% in the simeprevir-treated group and 37% in the placebo-treated group. Volume 49, April 2014
Secondary Endpoint(s)
• Rapid viral response was achieved in 77% of the simeprevir-treated group.
• On-treatment failure rate was 3% in the simeprevir-treated group and 27% in the placebo-treated group.
• Relapse rate was 18% in the simeprevir-treated group and 48% in the placebo-treated group.
• SVR12 for patients with genotype 1a virus was 70% in the simeprevir-treated group and 28% in the placebo-treated group. Among those without the Q80K polymorphism, SVR12 was achieved in 78% in the simeprevir group and 26% in the placebo group. Among those with the Q80K polymorphism, SVR12 was achieved in 47% in the simeprevir group and 30% in the placebo group.
• SVR12 for patients with genotype 1b virus was achieved in 86% with simeprevir treatment compared with 43% in the placebo group.
• SVR12 for patients with a Metavir score of F0 to F2 was 82% in the simeprevir-treated group and 41% in the placebo-treated group.
• SVR12 for patients with a Metavir score of F3 to F4 was 73% in the simeprevir-treated group and 24% in the placebo-treated group. Comments: Response rates were higher in the simeprevir-treated patients compared with the placebo treatment group when assessed by gender, age, race, BMI, HCV genotype/subtype, baseline HCV RNA load, prior HCV therapy, Metavir fi brosis score, and IL28B genotype. Limitations: Data are only available in the prescribing information. [21] [22] [23] [24] Study Design: Randomized, phase 2b, doubleblind, placebo-controlled, multicenter study Study Funding: Tibotec Pharmaceuticals Patients: 462 treatment-experienced adults with chronic HCV genotype-1 infection and HCV RNA greater than 10,000 units/mL (86% had HCV RNA greater than 800,000 units/mL; 58% with genotype 1b; 19% with F3 METAVIR score and 18% with F4 score; 12% with NS3 Q80K polymorphism at baseline) were included in the intent-to-treat analysis; median age was 50 years, 67% of patients were male and 93% were White. Patients had to have been treated with at least 1 previous course of peginterferon and ribavirin and were classifi ed as null responders (less than 2 log 10 reduction in HCV RNA by week 12; 25% of patients), partial responders (at least 2 log 10 reduction in HCV RNA by week 12; detectable HCV RNA at end of treatment; 35% of patients), or relapsers (HCV RNA undetectable at end of treatment; detectable within 24 weeks posttreatment; 40% of patients); 91.6% of patients completed the study. Intervention: Patients were randomized to 1 of 7 treatment arms:
Drug: Simeprevir plus Peginterferon and Ribavirin vs Placebo plus Peginterferon and Ribavirin
• Simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 12 weeks followed by placebo plus peginterferon and ribavirin for 36 weeks.
• Simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 12 weeks followed by placebo plus peginterferon and ribavirin for 36 weeks.
• Simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 24 weeks followed by placebo plus peginterferon and ribavirin for 24 weeks.
• Simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 24 weeks followed by placebo plus peginterferon plus ribavirin for 24 weeks.
• Simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 48 weeks.
• Simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 48 weeks.
• Placebo plus peginterferon and ribavirin for 48 weeks Peginterferon was administered at a dose of 180 mcg subcutaneously once weekly. Ribavirin was administered orally at a dose of 1,000 or 1,200 mg/day. All study medication was discontinued in patients not achieving at least a 1 log 10 reduction in HCV RNA at week 4, a 2 log 10 reduction at week 12, or HCV RNA less than 25 units/mL at weeks 24 or 36; study medication was also discontinued in patients with viral breakthrough.
Results Primary Endpoint(s)
• SVR24: 70% with simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 12 weeks followed by placebo and peginterferon plus ribavirin for 36 weeks (P < .001 vs control; NNT, 2.2); 67% with simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 12 weeks followed by placebo and peginterferon plus ribavirin for 36 weeks (P < .001 vs control; NNT, 2.3); 66% with simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 24 weeks followed by placebo and peginterferon plus ribavirin for 24 weeks (P < .001 vs control; NNT, 2.4); 72% with simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 24 weeks followed by placebo and peginterferon plus ribavirin for 24 weeks (P < .001 vs control; NNT, 2.1); 61% with simeprevir 100 mg PO once daily, peginterferon, and ribavirin for 48 weeks (P < .001 vs control; NNT, 2.7); 80% with simeprevir 150 mg PO once daily, peginterferon, and ribavirin for 48 weeks (P < .001 vs control; NNT, 1.8); 23% with placebo, peginterferon, and ribavirin for 48 weeks.
Secondary Endpoint(s)
• Rapid viral response (HCV RNA undetectable at week 4) was achieved in 53% to 68% of patients receiving a simeprevir-containing regimen compared with 1.5% receiving placebo; among patients achieving a rapid viral response, 90% and 86% in the simeprevir 100 and 150 mg groups, respectively, achieved SVR24.
• SVR12 was achieved in 61% to 80% of simeprevir-treated patients compared with 23% treated with placebo.
• Neutropenia, rash, and pruritus occurred more frequently during simeprevir treatment; fatigue scores did not differ between treatment groups.
Endpoint(s)
• Table 2 summarizes the SVR24 results by previous treatment response (prior null responder, prior partial responder, or prior relapser).
• The main reasons for failure to achieve SVR in the simeprevir-treated patients were viral breakthrough (10.9%) and relapse (11.9%), and the majority of these patients (92.6%) had emerging mutations with reduced in vitro susceptibility to simeprevir.
25
• ASPIRE allowed patients with a Metavir score of F3/F4 (moderate periportal infl ammation, piecemeal necrosis or severe focal cell damage, some fi brosis, and no obvious cirrhosis to severe periportal infl ammation, piecemeal necrosis or bridging necrosis, and cirrhosis) to be enrolled. The SVR24 in the treatment-experienced F3 patients was 48% with simeprevir, peginterferon, and ribavirin versus 8% with placebo plus peginterferon and ribavirin. The SVR24 in the treatment-experienced F4 patients was 62% with simeprevir, peginterferon, and ribavirin versus 0% with placebo plus peginterferon and ribavirin. 15 • In prior null responders, SVR24 rates with simeprevir 150 mg were 42% for genotype 1a and 58% for genotype 1b, compared with 0% and 33%, respectively, with placebo. Simeprevir response rates did not differ between patients with the Q80K polymorphism and those without the polymorphism. Comments: Higher responses occurred with all drug regimens containing simeprevir and were generally similar or higher when the dose of simeprevir was 150 mg. 22, 23 The study was conducted in 14 countries in Europe, North America, Australia, and New Zealand; the percentage of patients enrolled in each region was not provided. Limitations: This is a phase 2 study assessing multiple doses and regimens; results of a phase 3 study in treatment-experienced patients are not yet available.
CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS Contraindications
Contraindications for simeprevir are similar to those found in the boceprevir and telaprevir labeling (see Table 3 ).
Warnings and Precautions
Simeprevir must not be used as monotherapy. It should be used in conjunction with peginterferon alfa and ribavirin, and the contraindications, warnings, and precautions associated with those therapies must be heeded. The warnings and precautions for simeprevir, boceprevir, and telaprevir are compared in Table 4 .
Photosensitivity reactions have been observed during therapy with simeprevir plus peginterferon alfa and ribavirin, including serious reactions resulting in hospitalization. Photosensitivity reactions occurred most frequently within the fi rst 4 weeks of combined therapy with simeprevir, peginterferon alfa, and ribavirin, but can occur at any time during treatment. It may present as an exaggerated sunburn reaction, usually affecting areas exposed to light, and manifest with burning, erythema, exudation, blistering, and edema. Discontinuation of therapy may be necessary for some patients. Rash has also been observed in patients treated with a regimen of simeprevir, peginterferon, and ribavirin. It has occurred most frequently in the fi rst 4 weeks of therapy, but can occur at any time during treatment. Although most events have been of mild to moderate severity, severe rash and rash requiring discontinuation of therapy have been reported. Patients with mild to moderate rash should be followed for possible rash progression, with discontinuation of therapy advised if the rash becomes severe. 1 Simeprevir contains a sulfonamide moiety. Although an increased incidence of rash or photosensitivity were not observed in the small number of patients with a history of sulfa allergy exposed to simeprevir in clinical trials (n = 16), the risk of adverse reactions associated with sulfa allergy cannot be excluded. 1 Higher simeprevir exposure has also been observed in patients of East Asian ancestry, potentially increasing the frequency of adverse reactions including rash and photosensitivity. 1 The safety and effi cacy of simeprevir have not been studied in patients with moderate or severe hepatic impairment (Child Pugh class B or C). Simeprevir exposure may be increased, resulting in an increased frequency of adverse reactions including rash and photosensitivity. No specifi c recommendations for dosage adjustment are available. 1 No simeprevir dose adjustment is required in patients with mild, moderate, or severe renal impairment. 1 Because of the embryo-fetal toxicity associated with the required ribavirin therapy, female patients of childbearing potential and their male partners, as feron, and ribavirin compared with peginterferon and ribavirin alone with no increase in severity. 26 The addition of simeprevir to a peginterferon and ribavirin regimen did not change the incidence of patientreported fatigue. 16 There were no differences between treatment groups in hemoglobin, neutrophils, platelets, AST, ALT, amylase, or serum creatinine. Increased alkaline phosphatase and hyperbilirubinemia were observed more frequently in simeprevir-treated patients than in placebo-treated patients. Elevations in bilirubin were generally mild to moderate, peaked within the fi rst 2 weeks of therapy, and were rapidly reversible upon cessation of simeprevir.
1 Increases in total (direct and indirect) bilirubin without concomitant changes in ALT or AST have been potentially attributed to a reversible inhibition of OATP1B1 and MRP2 transporters.
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DRUG INTERACTIONS
Coadministration of simeprevir with moderate or strong inducers or inhibitors of CYP3A is not recommended because such combinations may lead to lower or higher simeprevir exposure.
1 Simeprevir does not affect CYP2C9, CYP2C19, or CYP2D6. It does mildly inhibit CYP1A2 and CYP3A4 activity, but does not inhibit hepatic CYP3A4 activity. Coadwell as male patients and their female partners, must use 2 effective contraceptive methods during treatment and for at least 6 months after completion of treatment. Routine monthly pregnancy tests must be performed during this time. 1 Breast-feeding should be done with caution. It is not known if simeprevir or its metabolites are excreted in human breast milk. It can be detected in a suckling rat, indicating the drug is excreted in milk. A decision should be made regarding breastfeeding based on the potential risk to the infant and the importance of therapy to the mother; the manufacturer recommends that either the drug or breastfeeding should be discontinued.
1
ADVERSE REACTIONS
Adverse reactions occurring with at least 3% higher frequency in subjects treated with simeprevir 150 mg once daily in combination with peginterferon alfa and ribavirin than in subjects treated with placebo with peginterferon alfa and ribavirin are summarized in Table 5 . 1 The most frequently reported adverse reactions associated with simeprevir-containing regimens included fatigue, headache, pruritus, infl uenza-like illness, rash, neutropenia, and nausea. 10, 11, 18, 20, 26 The incidence of adverse reactions might be slightly higher with simeprevir, peginter- ministration with CYP3A4 substrates may result in increased concentrations of these drugs. Simeprevir also inhibits OATP1B1/3 and P-glycoprotein transporters, potentially resulting in increased plasma concentrations of drugs that are substrates for these transporters.
1 Table 6 lists the established or potentially signifi cant drug interactions associated with simeprevir. 1 No dose adjustments are needed for either drug when simeprevir is administered with caffeine, dextromethorphan, escitalopram, ethinyl estradiol plus norethindrone, methadone, midazolam (intravenous), omeprazole, raltegravir, rilpivirine, and tenofovir disoproxil fumarate. [27] [28] [29] In addition, no clinically important interactions are anticipated when simeprevir is administered with antacids; the corticosteroids budesonide, fl uticasone, methylprednisolone, and prednisone; fl uvastatin; H 2 -receptor antagonists; the narcotic analgesics buprenorphine and naloxone; the nucleoside reverse transcriptase inhibitors abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine; maraviroc; methylphenidate; and proton pump inhibitors.
1
RECOMMENDED MONITORING
The monitoring requirements for simeprevir are less than those recommended with boceprevir and telaprevir therapy (see Table 7 ). Hematologic monitoring is recommended at baseline and at weeks 2 and 4 of ribavirin therapy, and then as clinically appropriate.
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DOSING
The recommended dose of simeprevir is 150 mg once daily with food. In all patients, simeprevir therapy should be initiated in combination with peginterferon alfa and ribavirin and continued for 12 weeks. Treatment-naive patients and prior relapsers, including those with cirrhosis, should receive an additional 12 weeks of therapy with peginterferon alfa and ribavirin (total treatment duration, 24 weeks). Prior nonresponders (partial and null responders), including those with cirrhosis, should receive an additional 36 weeks of peginterferon and ribavirin (total treatment duration, 48 weeks). 1 Patients failing to achieve a virologic response while on therapy are unlikely to achieve a sustained virologic response; therefore, therapy should be discontinued in patients with an HCV RNA of 25 units/mL or greater at weeks 4, 12, or 24.
1
Boceprevir is dosed as four 200 mg capsules 3 times daily with food, starting after 4 weeks of peginterferon and ribavirin therapy continuing for up to 44 weeks. 2 Sofosbuvir is dosed as 400 mg once daily with or without food for 12 weeks in patients with genotype 1 (with peginterferon and ribavirin), 2 (with ribavirin), or 4 (with peginterferon and ribavirin), and 24 weeks in genotype 3 (with ribavirin). 4 Telaprevir is dosed as three 375 mg tablets twice daily with food (meal or snack containing at least 20 g of fat) for 12 weeks with peginterferon and ribavirin; peginterferon and ribavirin therapy follows for an additional 12 or 36 weeks, depending on viral response and prior response status. 3 
PRODUCT AVAILABILITY
Simeprevir received FDA approval on November 22, 2013. 31 It is available as 150 mg capsules supplied in bottles of 7 or 28 capsules. Simeprevir capsules should be stored in the original bottle to protect the product from light and at temperatures below 30°C (86°F).
1
DRUG SAFETY/RISK EVALUATION AND MITIGATION STRATEGY (REMS)
No REMS was required for simeprevir approval.
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CONCLUSION
Simeprevir is an HCV NS3/4A protease inhibitor that will be useful in combination with peginterferon alfa and ribavirin in the treatment of chronic HCV genotype 1 in adult patients with compensated 
